Cargando…

Predicting the course of Alzheimer’s progression

Alzheimer’s disease is the most common neurodegenerative disease and is characterized by the accumulation of amyloid-beta peptides leading to the formation of plaques and tau protein tangles in brain. These neuropathological features precede cognitive impairment and Alzheimer’s dementia by many year...

Descripción completa

Detalles Bibliográficos
Autores principales: Iddi, Samuel, Li, Dan, Aisen, Paul S., Rafii, Michael S., Thompson, Wesley K., Donohue, Michael C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598897/
https://www.ncbi.nlm.nih.gov/pubmed/31254120
http://dx.doi.org/10.1186/s40708-019-0099-0
_version_ 1783430854498844672
author Iddi, Samuel
Li, Dan
Aisen, Paul S.
Rafii, Michael S.
Thompson, Wesley K.
Donohue, Michael C.
author_facet Iddi, Samuel
Li, Dan
Aisen, Paul S.
Rafii, Michael S.
Thompson, Wesley K.
Donohue, Michael C.
author_sort Iddi, Samuel
collection PubMed
description Alzheimer’s disease is the most common neurodegenerative disease and is characterized by the accumulation of amyloid-beta peptides leading to the formation of plaques and tau protein tangles in brain. These neuropathological features precede cognitive impairment and Alzheimer’s dementia by many years. To better understand and predict the course of disease from early-stage asymptomatic to late-stage dementia, it is critical to study the patterns of progression of multiple markers. In particular, we aim to predict the likely future course of progression for individuals given only a single observation of their markers. Improved individual-level prediction may lead to improved clinical care and clinical trials. We propose a two-stage approach to modeling and predicting measures of cognition, function, brain imaging, fluid biomarkers, and diagnosis of individuals using multiple domains simultaneously. In the first stage, joint (or multivariate) mixed-effects models are used to simultaneously model multiple markers over time. In the second stage, random forests are used to predict categorical diagnoses (cognitively normal, mild cognitive impairment, or dementia) from predictions of continuous markers based on the first-stage model. The combination of the two models allows one to leverage their key strengths in order to obtain improved accuracy. We characterize the predictive accuracy of this two-stage approach using data from the Alzheimer’s Disease Neuroimaging Initiative. The two-stage approach using a single joint mixed-effects model for all continuous outcomes yields better diagnostic classification accuracy compared to using separate univariate mixed-effects models for each of the continuous outcomes. Overall prediction accuracy above 80% was achieved over a period of 2.5 years. The results further indicate that overall accuracy is improved when markers from multiple assessment domains, such as cognition, function, and brain imaging, are used in the prediction algorithm as compared to the use of markers from a single domain only.
format Online
Article
Text
id pubmed-6598897
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-65988972019-07-18 Predicting the course of Alzheimer’s progression Iddi, Samuel Li, Dan Aisen, Paul S. Rafii, Michael S. Thompson, Wesley K. Donohue, Michael C. Brain Inform Research Alzheimer’s disease is the most common neurodegenerative disease and is characterized by the accumulation of amyloid-beta peptides leading to the formation of plaques and tau protein tangles in brain. These neuropathological features precede cognitive impairment and Alzheimer’s dementia by many years. To better understand and predict the course of disease from early-stage asymptomatic to late-stage dementia, it is critical to study the patterns of progression of multiple markers. In particular, we aim to predict the likely future course of progression for individuals given only a single observation of their markers. Improved individual-level prediction may lead to improved clinical care and clinical trials. We propose a two-stage approach to modeling and predicting measures of cognition, function, brain imaging, fluid biomarkers, and diagnosis of individuals using multiple domains simultaneously. In the first stage, joint (or multivariate) mixed-effects models are used to simultaneously model multiple markers over time. In the second stage, random forests are used to predict categorical diagnoses (cognitively normal, mild cognitive impairment, or dementia) from predictions of continuous markers based on the first-stage model. The combination of the two models allows one to leverage their key strengths in order to obtain improved accuracy. We characterize the predictive accuracy of this two-stage approach using data from the Alzheimer’s Disease Neuroimaging Initiative. The two-stage approach using a single joint mixed-effects model for all continuous outcomes yields better diagnostic classification accuracy compared to using separate univariate mixed-effects models for each of the continuous outcomes. Overall prediction accuracy above 80% was achieved over a period of 2.5 years. The results further indicate that overall accuracy is improved when markers from multiple assessment domains, such as cognition, function, and brain imaging, are used in the prediction algorithm as compared to the use of markers from a single domain only. Springer Berlin Heidelberg 2019-06-28 /pmc/articles/PMC6598897/ /pubmed/31254120 http://dx.doi.org/10.1186/s40708-019-0099-0 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Iddi, Samuel
Li, Dan
Aisen, Paul S.
Rafii, Michael S.
Thompson, Wesley K.
Donohue, Michael C.
Predicting the course of Alzheimer’s progression
title Predicting the course of Alzheimer’s progression
title_full Predicting the course of Alzheimer’s progression
title_fullStr Predicting the course of Alzheimer’s progression
title_full_unstemmed Predicting the course of Alzheimer’s progression
title_short Predicting the course of Alzheimer’s progression
title_sort predicting the course of alzheimer’s progression
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598897/
https://www.ncbi.nlm.nih.gov/pubmed/31254120
http://dx.doi.org/10.1186/s40708-019-0099-0
work_keys_str_mv AT iddisamuel predictingthecourseofalzheimersprogression
AT lidan predictingthecourseofalzheimersprogression
AT aisenpauls predictingthecourseofalzheimersprogression
AT rafiimichaels predictingthecourseofalzheimersprogression
AT thompsonwesleyk predictingthecourseofalzheimersprogression
AT donohuemichaelc predictingthecourseofalzheimersprogression
AT predictingthecourseofalzheimersprogression